Acute respiratory distress syndrome (or ARDS) is characterized by an acute respiratory failure associated with an intense inflammatory response and lung injury. It's observed an increase of pulmonary vascular permeability and consequent alveolar flooding and collapse. There is also a massive migration of inflammatory cells such as neutrophils and macrophages, which have a fundamental role on its pathophysiology. ARDS can be explained by multiple etiologies and is a disease with a high impact on hospital admissions and patient's mortality, especially in the ICU. ARDS's mortality rate is around 40% and is responsible for 10-15% of all ICU admissions. Despite the existence of several studies abut its pathophysiology, there's a great absence of specific and targeted therapies for ARDS. Currently, the treatment of ARDS is based on support therapy and, therefore, it's of paramount importance that is researched alternative therapies for this syndrome which can change the prognosis of those patients. That said, glycine and anti-IL17 have been showing an important immunomodulatory activity, reducing inflammatory response of both neutrophils and macrophages. Also by reducing their response, it reduces inflammation, cytokine secretion and consequently the acute pulmonary injury. Although, there's no studies associating these two possible treatments on ARDS. Objective: Evaluate and study the inflammatory response, oxidative stress, extracellular matrix remodeling and functional repercussions to the use of glycine and anti-IL17, both as a preventive and a therapeutic measure on an experimental model.
News published in Agência FAPESP Newsletter about the scholarship: